Tarsons Products
add_icon

Tarsons Products

231.82
+0.77
(0.33%)
Market Cap
₹1,229.30 Cr
PE Ratio
57.09
Volume
1,92,679.00
Day High - Low
₹234.00 - ₹226.31
52W High-Low
₹464.30 - ₹198.00
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
1,229.30 Cr
EPS
5.60
PB Ratio
1.88
Book Value
117.77
EBITDA
126.70
Dividend Yield
0.00 %
Industry
Healthcare
ROE Growth %
-
Debt to Equity
0.49
Analyst Rating and Forecast
- By Refinitiv from1 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Mitsubishi UFJ Financial Group sold its indirect interest in Tarsons Products Ltd by divesting First Sentier Investors (Hong Kong) Limited on November 25, 2025, reducing its shareholding from 5.28% to 1.43%. The transaction involved the sale of 2,050,177 shares, leaving MUFG with 759,560 shares in the Indian company out of total voting capital of 53,206,281 shares.
neutral
Tarsons Products has invested €3 million in its Singapore subsidiary Tarsons Life Science Pte. Ltd. The investment is intended for loan payments and business operations of the subsidiary.
neutral
Tarsons Products Limited reported revenue growth to INR 81 crores in Q2 FY26 with EBITDA rising 11% year-on-year to INR 26 crores, but profit after tax declined to INR 6.5 crores from INR 12.9 crores due to higher depreciation from capacity expansion. The company expects its Panchla and Amta facilities to be fully operational by Q4 FY26, with peak revenue potential of INR 350-400 crores from the new capacity over the next 3-5 years.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,916.90
#1 19,507.20
52.70
#1 1,759.00
22.62
#1 339
5.03
48.49
248.90
1,450.50
62.45
242.40
24.12
25
44.07
20.52
713.70
1,295.40
70.93
186.60
40.62
20
-
51.21
231.82
#4 1,229.30
#6 57.09
#2 408.40
#5 32.64
#3 30
#7 -67.96
38.22
598.05
1,003.70
67.58
249.37
43.89
17
-14.81
50.02
232.20
1,001.50
#1 22.88
326.67
41.78
46
751.52
52.22
329.90
631.00
41.70
136.30
#1 107.77
16
-
60.56
446.00
552.70
28.18
67.10
13.15
18
14.58
37.83
290.00
371.60
46.19
111.80
-
8
-
55.71
299.80
294.60
63.49
122.10
19.24
1
#1 820.00
64.69
Growth Rate
Revenue Growth
32.64 %
Net Income Growth
-30.05 %
Cash Flow Change
11.23 %
ROE
-32.18 %
ROCE
-23.98 %
EBITDA Margin (Avg.)
-14.19 %

Quarterly Financial Results

Quarterly Financials
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
62
68
71
77
73
88
65
109
88
108
97
117
95
108
Expenses
30
33
32
38
38
41
39
76
66
74
66
76
67
75
EBITDA
32
36
39
40
36
47
26
34
22
34
31
41
28
33
Operating Profit %
51 %
52 %
53 %
50 %
47 %
52 %
37 %
29 %
22 %
26 %
31 %
33 %
27 %
27 %
Depreciation
4
3
5
5
5
7
10
12
11
14
17
20
20
23
Interest
1
1
1
2
1
0
3
4
4
5
5
5
5
5
Profit Before Tax
28
32
33
34
29
39
14
17
6
15
8
16
3
6
Tax
7
8
9
9
7
10
4
7
2
5
3
5
1
2
Net Profit
21
24
25
25
22
30
10
10
4
10
5
10
2
3
EPS in ₹
4.13
4.59
4.88
4.89
4.14
5.69
1.87
1.94
0.75
1.93
0.99
1.92
0.34
0.62

Balance Sheet

Balance Sheet
2021
2022
2024
2025
Total Assets
296
544
972
1,080
Fixed Assets
120
189
336
536
Current Assets
113
245
235
243
Capital Work in Progress
22
32
267
233
Investments
0
0
0
0
Other Assets
153
323
369
311
Total Liabilities
296
544
972
1,080
Current Liabilities
42
35
213
176
Non Current Liabilities
10
20
146
274
Total Equity
244
490
613
630
Reserve & Surplus
244
479
602
620
Share Capital
0
11
11
11

Cash Flow

Cash Flow
2021
2022
2024
2025
Net Cash Flow
-23
75
-47
8
Investing Activities
-64
-138
-285
-145
Operating Activities
68
84
103
114
Financing Activities
-27
130
136
39

Share Holding

% Holding
Aug 2021
Nov 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
50.99 %
47.30 %
47.30 %
47.31 %
47.31 %
47.31 %
47.31 %
47.31 %
47.31 %
47.31 %
47.31 %
47.31 %
47.31 %
47.31 %
47.31 %
47.31 %
47.31 %
47.31 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
8.16 %
7.95 %
8.04 %
7.51 %
9.52 %
9.14 %
5.82 %
DIIs
0.00 %
6.92 %
6.03 %
7.66 %
7.39 %
8.13 %
8.52 %
8.45 %
7.38 %
3.16 %
2.15 %
0.18 %
0.12 %
0.21 %
0.50 %
0.29 %
0.04 %
0.08 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
13.55 %
11.50 %
10.28 %
9.94 %
9.19 %
9.56 %
10.00 %
11.35 %
11.64 %
12.77 %
13.44 %
13.53 %
13.06 %
15.37 %
15.30 %
15.42 %
17.14 %
Others
49.01 %
32.23 %
35.17 %
34.75 %
35.36 %
35.37 %
34.62 %
34.25 %
33.96 %
37.90 %
37.78 %
30.92 %
31.10 %
31.39 %
29.31 %
27.58 %
28.09 %
29.65 %
No of Share Holders
8
61
1,59,891
1,25,714
1,12,227
1,07,011
1,07,945
1,05,304
1,07,440
1,08,236
1,07,564
1,02,866
1,05,330
99,586
96,927
93,417
90,891
88,966

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.66 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
20 Sept 2024 DIVIDEND Dividend
₹ 2.00 /share
20 Sept 2024 418.95 468.70
27 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
27 Sept 2024 465.20 452.15
07 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Nov 2024 406.65 419.00
14 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Feb 2025 364.55 329.95
28 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 May 2025 386.30 431.20
12 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Aug 2025 371.20 373.10
22 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
22 Sept 2025 373.10 309.15
12 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Nov 2025 289.05 268.10

Announcements

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 20115 days ago
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Further Investment In Tarsons Life Science Pte. Ltd. A Wholly-Owned Subsidiary Of The Company.6 days ago
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 19, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Nov 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 13, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationNov 13, 2025
Results For The Quarter And Half Year Ended September 30 2025Nov 12, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held On Wednesday November 12 2025Nov 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 08, 2025
Board Meeting Intimation for Considering And Approving The Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30 2025Nov 04, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 09, 2025
Closure of Trading WindowSep 25, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 24, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 22, 2025
Reg. 34 (1) Annual Report.Sep 18, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 31, 2025
Business Responsibility and Sustainability Reporting (BRSR)Aug 30, 2025
Notice Of The 42Nd Annual General Meeting Of The Company For The Financial Year Ended 31St March 2025.Aug 30, 2025
Reg. 34 (1) Annual Report.Aug 30, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 27, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 22, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 19, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 12, 2025
Announcement Under Regulation 30 (LODR) Regulations 2015Aug 12, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 12, 2025
Adoption Of Unaudited Financial Results For The Quarter Ended 30Th June 2025Aug 12, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held On Tuesday 12Th August 2025 For The Quarter Ended 30Th June 2025.Aug 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 06, 2025
Board Meeting Intimation for Considering And Approving The Unaudited Standalone & Consolidated Financial Results Of The Company For The First Quarter Ended 30Th June 2025.Aug 06, 2025
Announcement under Regulation 30 (LODR)-Resignation of DirectorAug 04, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateAug 04, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementAug 04, 2025
Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015Jul 23, 2025
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJul 23, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJul 23, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 14, 2025
Closure of Trading WindowJun 25, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotJun 21, 2025
Announcement under Regulation 30 (LODR)-Credit RatingJun 20, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 03, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 30, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 29, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 29, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 28, 2025
Approved Annual Audited Financial Results For The Year Ended 31St March 2025May 28, 2025
Board Meeting Outcome for Approved The Audited Standalone And Consolidated Financial Results For The Quarter And Financial Year Ended 31St March 2025May 28, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Bandhan BSE Healthcare Index Fund Direct-Growth
0.03%
1
-0.01%
-0.01%

Technical Indicators

RSI(14)
Neutral
37.51
ATR(14)
Less Volatile
12.68
STOCH(9,6)
Neutral
59.97
STOCH RSI(14)
Overbought
99.95
MACD(12,26)
Bullish
1.84
ADX(14)
Strong Trend
48.06
UO(9)
Bearish
42.67
ROC(12)
Downtrend And Accelerating
-3.61
WillR(14)
Neutral
-45.86